---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021213"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T05:20:22.466542+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics Q1 net product sales up 26% to $29.6M; net loss narrows to $32.8M

## Summary
- Net product sales $29.6M vs $23.5M in Q1 2022, driven by oncology franchise growth of 15%.
- Net loss $32.8M ($0.27/share), improved from $63.9M ($0.63/share) a year ago.
- Cash and investments $60.0M at March 31, 2023, down from $84.9M at Dec. 31, 2022.
- Appointed Craig Collard as CEO in April; APONVIE launched in March with $0.3M initial sales.
- ZYNRELEF sNDA PDUFA date set for Oct. 23, 2023; 907 unique accounts have purchased since launch.

## SEC filing metadata
- accession: 0000950170-23-021213
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017023021213/0000950170-23-021213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017023021213/hrtx-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021213
- JSON: https://secwatch.observer/filing/0000950170-23-021213.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.